WM-S1

News alerts, weekly reports and conference planners

Company:

WMBIO

Drug class:

mtRTK inhibitor

‹

›

over2years

Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy. (PubMed, Cell Death Differ)

Here, we identified that presence of activated RON could be a possible factor for the development of resistance against anti-EGFR (cetuximab) therapy in colorectal cancer patient tissues. In terms of the immunotherapy, WM-S1-030 elicited notable antitumor immunity in anti-PD-1 resistant cell derived mouse model, likely via repression of M1/M2 polarization of macrophages. These findings suggest that WM-S1-030 could be developed as a new treatment option for cancer patients expressing these three RON variants.

over 2 years ago

Journal

KRAS (KRAS proto-oncogene GTPase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MST1R (Macrophage Stimulating 1 Receptor)

Erbitux (cetuximab) • WM-S1

almost4years

WM-S1, the novel small molecule inhibitor of mutant RTK/receptor tyrosine kinase, for the treatment of cancer (AACR 2022)

In conclusion, mtRTK is a potential oncogenic driver mutation in various solid tumor. A first-in-class anticancer agent WM-S1 targeting mtRTK can be promising therapeutic agents for cetuximab-resistant colon cancer patients regardless of KRAS mutation status and other cancers.

almost 4 years ago

PD(L)-1 Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS wild-type • RAS wild-type

Erbitux (cetuximab) • WM-S1